Naser Amirizadeh
Overview
Explore the profile of Naser Amirizadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Oodi A, Daneshvar Z, Goudarzi S, Amirizadeh N
Transfus Apher Sci
. 2020 Jul;
59(5):102870.
PMID: 32660892
Background: Most prevalent weak D types in the Caucasians molecularly defined weak D types 1, 2 or 3 and can be managed safely as RhD-positive, conserving limited supplies of RhD-negative...
12.
Jalali S, Oodi A, Azarkeivan A, Gudarzi S, Amirizadeh N
Indian J Hematol Blood Transfus
. 2020 Jul;
36(3):550-555.
PMID: 32647431
We aimed to determine the JK genotype in thalassemia patients from Iran using different molecular methods to compare with phenotyping results. We also aimed to standardize for the first time,...
13.
Sarihi R, Amirizadeh N, Oodi A, Azarkeivan A
Hemoglobin
. 2020 May;
44(1):31-36.
PMID: 32400249
The best approach for prevention of alloimmunization in β-thalassemia (β-thal) patients is perfect matching of all red blood cell (RBC) antigens associated with clinically significant antibodies, but this is expensive...
14.
Hashemi Tayer A, Amirizadeh N, Ahmadinejad M, Nikougoftar M, Reza Deyhim M, Zolfaghari S
Transfus Med Hemother
. 2019 Nov;
46(4):224-230.
PMID: 31700504
Background: Red blood cells (RBCs) undergo structural and biochemical alterations during storage which are collectively called RBC storage lesion and cause a decrease in RBC recovery and survival. During storage,...
15.
Sayyadipour F, Amirizadeh N, Oodi A, Khalili M, Saba F
Cardiovasc Hematol Disord Drug Targets
. 2019 Sep;
20(2):131-137.
PMID: 31533604
Aims: Factor VIII (FVIII) replacement therapy remains a primary treatment for hemophilia A, however, the development of FVIII antibodies (inhibitors) and short half-life of the FVIII products are the major...
16.
Arabkari V, Amirizadeh N, Nikougoftar M, Soleimani M
J Cell Physiol
. 2019 Apr;
234(11):20072-20084.
PMID: 30953369
Human umbilical cord blood (HUCB) is a suitable source of hematopoietic stem cells (HSCs) for therapeutic transplantation. Different approaches have been used to expand the number of HSCs to increase...
17.
Khosroshahi B, Oodi A, Namjou S, Gholamali T, Amirizadeh N
Indian J Hematol Blood Transfus
. 2019 Mar;
35(1):119-124.
PMID: 30828158
D antigen is the most important and immunogenic antigen of the Rh blood group. The RhD-negative phenotype has different genetic backgrounds with variable distribution in different populations. Hybrid , resulting...
18.
Jafarzadeh N, Safari Z, Pornour M, Amirizadeh N, Moghadam M, Sadeghizadeh M
J Cell Physiol
. 2018 Oct;
234(4):3697-3710.
PMID: 30317554
Leukemic cells can impact the bone marrow niche to create a tumor-favorable microenvironment using their secreted factors. Little knowledge is available about immunosuppressive and tumor-promoting properties of chronic myeloid leukemia...
19.
Kamali Dolatabadi E, Dehaghi M, Amirizadeh N, Parivar K, Mahdian R
Iran J Pharm Res
. 2018 Mar;
16(4):1600-1611.
PMID: 29552069
Aberrant DNA methylation has been reported as an important phenotype in acute myeloid leukemia. However the clinical significance of methylation changes has not been clear yet. In this study methylation...
20.
Ghasemzadeh M, Hosseini E, Ahmadi M, Kamalizad M, Amirizadeh N
Cytotechnology
. 2018 Jan;
70(2):729-739.
PMID: 29305674
So far, substantial attentions have been attracted to the application of mesenchymal stem or stromal cells (MSCs) in different therapeutic approaches. Although human bone marrow is commonly considered as a...